Sanofi and Regeneron 色界吧s have announced the preliminary results from the Phase 2 portion of an ongoing Phase 2/3 trial investigating Kevzara庐 (sarilumab), an interleukin-6 (IL-6) receptor antibody, in hospitalised patients with serious respiratory illness as a result of Covid-19.
Following a review by the Independent Data Monitoring Committee (IDMC) of all available Phase 2 and Phase 3 data, the trial will be immediately amended so that only 鈥渃ritical鈥� patients continue to be enrolled to receive Kevzara 400 mg or placebo.
The randomised Phase 2 portion of the trial compared intravenously-administered Kevzara higher dose (400 mg), Kevzara lower dose (200 mg) and placebo. It assessed 457 hospitalised patients, who were categorised at baseline as having either 鈥渟evere鈥� illness (28% of patients), 鈥渃ritical鈥� illness (49% of patients) or 鈥渕ulti-system organ dysfunction鈥� (MSOD) (23% of patients). Patients were classified as 鈥渟evere鈥� if they required oxygen supplementation without mechanical or high-flow oxygenation; or 鈥渃ritical鈥� if they required mechanical ventilation or high-flow oxygenation or required treatment in an intensive care unit.
Preliminary analysis of the Phase 2 portion of the trial demonstrated that Kevzara rapidly lowered C-reactive protein, a key marker of inflammation, meeting the primary endpoint (see table below).
Baseline levels of IL-6 were elevated across all treatment arms, with higher levels observed in 鈥渃ritical鈥� patients compared to 鈥渟evere鈥� patients. Additionally, no new safety findings were observed with the use of Kevzara in Covid-19 patients.
色界吧 of clinical outcomes in the Phase 2 trial was exploratory and pre-specified to focus on the 鈥渟evere鈥� and 鈥渃ritical鈥� groups. In the preliminary Phase 2 analysis, Kevzara had no notable benefit on clinical outcomes when combining the 鈥渟evere鈥� and 鈥渃ritical鈥� groups, versus placebo. However, there were negative trends for most outcomes in the 鈥渟evere鈥� group, while there were positive trends for all outcomes in the 鈥渃ritical鈥� group (see table below). Subsequent to the IDMC review, Regeneron and Sanofi conducted a review of the discontinued 鈥渟evere鈥� group that revealed the negative trends in Phase 2 (n=126) were not reproduced in Phase 3 (n=276), and that clinical outcomes were balanced across all treatment arms. Outcomes for the 鈥渟evere鈥� group were better than expected based on prior reports, regardless of treatment assignment: for example, in the Phase 2 portion, approximately 80% were discharged, 10% of patients died and 10% remain hospitalised.
鈥淓ven in a pandemic setting, it鈥檚 both crucial and possible to obtain controlled data in adequately-sized trials to provide the evidence needed to inform optimal medical care,鈥澛爏aid George D. Yancopoulos, M.D., Ph.D., Regeneron Co-Founder, President and Chief Scientific Officer.聽鈥淓merging evidence with Kevzara and other repurposed drugs in the Covid-19 crisis highlight the challenges of making decisions about existing medicines for new viral threats using small, uncontrolled studies. We await results of the ongoing Phase 3 trial to learn more about Covid-19 and better understand whether some patients may benefit from Kevzara treatment. In addition, there is an acute need for tailored approaches that specifically target this virus. To that end, Regeneron is rapidly advancing our targeted anti-SARS-CoV-2 antibody cocktail and we plan to initiate clinical trials in June.鈥�
The Kevzara trial was designed after a small (n=21), single-arm study in China (Xu et al) among mostly severe, febrile hospitalised Covid-19 patients, which found elevated IL-6 levels, and suggested that inhibiting this pathway with the IL-6 inhibitor tocilizumab rapidly reduced fever and improved oxygenation in severe patients, allowing for successful hospital discharge. These uncontrolled findings require confirmation in adequately-sized and well-controlled trials. 聽Last month, Regeneron and Sanofi moved rapidly to evaluate Kevzara in a prospective, randomised, placebo-controlled adaptively-designed U.S. Phase 2/3 trial in collaboration with U.S. groups including the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, the Food and Drug Administration (FDA), and hospitals across the country.
“At Sanofi, we are committed to helping combat the global Covid-19 pandemic.聽 As we quickly follow the science to better understand this disease and explore how best to treat patients, these initial results from the randomised clinical trial setting provide physicians much-needed insights and information regarding Kevzara for patients with Covid-19,鈥� 聽said聽John Reed, M.D., Ph.D., Sanofi’s Global Head of Research and Development.聽鈥淲hile our evaluation of the use of Kevzara for Covid-19 treatment remains an investigational approach, Sanofi continues to stay at the forefront of multiple initiatives to fight this disease, including researching other potential treatment options, developing vaccine candidates that can be manufactured at large-scale, and potential collaboration for an innovative SARS-CoV-2聽smartphone-based self-testing solution.鈥�
The ongoing portion of the Phase 3 trial, which is continuing to enrol, currently includes more than 600 patients in the 鈥渃ritical鈥� group.聽 Regeneron and Sanofi remain blinded to the ongoing portion of the Phase 3 trial and expect to report results by June.
In addition, the companies are also conducting a second trial in countries outside of the U.S. The Phase 3 trial of Kevzara in approximately 400 patients hospitalised with Covid-19 infection is currently enrolling in Italy, Spain, Germany, France, Canada, Russia, Israel and Japan. Initial results from this second trial are expected in the third quarter. The findings from the U.S. trial will be shared immediately with the IDMC and similar amendments to the trial outside the U.S. will be considered.
The U.S. Kevzara trial has been funded in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; and BARDA, under OT number: HHSO100201700020C.
The use of Kevzara to treat the symptoms of Covid-19 is investigational and has not been fully evaluated by any regulatory authority.
For more information, please fill out the enquiry form attached to this page.